Observational studyNeurourology and urodynamics2025
Widespread Pain Moderates the Response to Centrally-Acting Therapies in an Observational Cohort of Patients With Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study.
Observational study in Neurourology and urodynamics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MAPP Research Network: Trans-MAPP Study of Urologic Chronic Pelvic Pain: Symptom Patterns Study (SPS)
Trans-MAPP Study of Urologic Chronic Pelvic Pain: Control Study Protocol
Who cites it
8 citing papers in PubMed.
- Epigenetic Regulation of Immune Dysfunction in Chronic Prostatitis/Chronic Pelvic Pain Syndrome.The Prostate · 2026Article
- A Self-Reported Electronic Body Map Identifies Distinct Clinical Pain Phenotypes in Chronic Pancreatitis.Clinical and translational gastroenterology · 2026Article
- Data-driven diagnosis and clinical presentation of high-tone pelvic floor dysfunction.American journal of obstetrics and gynecology · 2026Article
- A Review of NIDDK-Funded Studies of Urological Chronic Pain Conditions.Neurourology and urodynamics · 2026Review
- Integrating vaginal laser therapy into multidisciplinary management of bladder pain syndrome and vulvodynia.BMC urology · 2026Review
- Prostatitis-Related Male Infertility: From Inflammation and Dysbiosis to Sperm DNA Damage.Diagnostics (Basel, Switzerland) · 2026Review
- Correlates of Positive Response to Therapeutic Hydrodistension in Interstitial Cystitis/Bladder Pain Syndrome.Neurourology and urodynamics · 2026Article
- Psychological and Behavioral Contributors to Lower Urinary Tract Dysfunction: Trauma, Stress, and Neurobiological Pathways.Current bladder dysfunction reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
purposeUrologic Chronic Pelvic Pain Syndrome (UCPPS) impacts millions of people in the United States but treatment options remain largely unsatisfying. A large number of neurobiological studies from the Multidisciplinary Approach to the study of chronic Pelvic Pain (MAPP) research network and others point to aberrant pain mechanisms in patients with UCPPS and widespread pain, but the clinical significance of widespread pain has been speculative. MATERIALS AND
methodsIn the current exploratory study we investigated whether pain and urologic symptoms responded to centrally-directed therapies (tricyclic antidepressants/gabapentinoids) versus peripherally-directed (pelvic floor physical therapy/hydrodistension) therapies depending on the presence or absence of widespread pain when the new treatment was initiated. RESULTS AND
conclusionsForty UCPPS patients (n = 19 widespread) underwent an evaluation of UCPPS symptoms before and after twelve weeks of either centrally-directed (n = 16) or peripherally-directed therapy. Participants were stratified post hoc into widespread (two or more non-pelvic pain sites + pelvic pain) and localized pain categories. General linear models were used to test the group X treatment interaction effect, adjusting for age, sex, and baseline outcome levels. On average, patients with widespread pain receiving centrally-directed therapies improved more than six points on the 0-28 Pelvic Pain Severity scale, while those with localized pain showed no average improvement (interaction p = 0.005). Similar effects were observed for the bladder symptom impact score (interaction p = 0.011) but not urologic symptom severity (interaction p = 0.72). While these findings are exploratory, they provide preliminary evidence for phenotype X treatment interactions in UCPPS and should be followed by confirmatory studies.
trial registrationClinicalTrials.gov Identifier: NCT02514265-MAPP Research Network: Trans-MAPP Study of Urologic Chronic Pelvic Pain: Symptom Patterns Study (SPS). CLINICALTRIALS: gov Identifier: NCT02898220-Trans-MAPP Study of Urologic Chronic Pelvic Pain: Control Study Protocol.xs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.